<DOC>
	<DOCNO>NCT00659022</DOCNO>
	<brief_summary>Study Hypothesis • As well animal model patient colorectal cancer resection primary tumor result increase vascular density , metabolism secondary tumor growth distant metastasis . These data strongly suggest inhibitory effect primary tumor outgrowth metastasis . In study investigate whether pre-operative treatment anti-angiogenic agent bevacizumab and/or chemotherapy resection primary colorectal tumor shift balance angiogenic anti-angiogenic factor favor anti-angiogenic factor result reduce growth liver metastasis . Eligibility - Histological proven colorectal cancer without sign bowel obstruction bleed - Synchronous liver metastasis - WHO performance status 0-1 Treatment - Arm A : immediate surgery primary colorectal tumor , neoadjuvant therapy - Arm B : neoadjuvant treatment bevacizumab 7 week prior surgery colorectal primary - Arm C : neoadjuvant treatment CAPOX 7 week prior surgery colorectal primary - Arm D : neoadjuvant treatment bevacizumab CAPOX 7 week prior surgery colorectal primary Primary endpoint Difference response liver metastases resection primary tumor experimental group control group , determine histopathological score vascular density , apoptotic mitotic index measurement metabolic activity liver metastases FDG-PET SUV measurement . Secondary endpoint Toxicity neo-adjuvant treatment Complications surgery</brief_summary>
	<brief_title>Neo-adjuvant Therapy Effect Synchronous Metastatic Growth</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients histological proven primary colorectal cancer synchronous unresectable liver metastasis without additional extrahepatic disease ( primary tumor situ ) . Unresectable liver metastasis define extensive hepatic involvement extrahepatic disease . Measurable liver metastasis CT scan ( RECIST ) , positive signal liver metastases FDGPET scan Age : 1880 year WHO performance scale 01 ASA category I II Negative pregnancy test woman childbearing potential Life expectancy &gt; 12 week Laboratory value obtain ≤ 3 week prior study entry , disease evaluation perform ≤ 3 week prior study entry . Adequate bone marrow function ( Hb &gt; 6.5 mmol/L , absolute neutrophil count &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L ) , renal function ( serum creatinine &lt; 1.5 x ULN creatinine clearance ≥ 50 mL/min ( calculate accord Cockroft Gault ) , liver function ( ASAT ALAT ≤ 3 x upper normal limit , serum bilirubin ≤ 2 x upper normal limit ) Written informed consent Signs bowel obstruction bleed primary tumor Prior chemotherapy treatment advance disease , prior treatment antiangiogenic drug Resectable liver metastasis Diabetes mellitus Continuous use immunosuppressive agent Pregnancy lactation Contraindications systemic therapy bevacizumab ( Avastin ) / chemotherapy ( Xelox ) Concurrent severe uncontrolled disease ( i.e . uncontrolled hypertension , congestive heart failure , myocardial infarction &lt; 12 month , chronic active infection ) Sensory neuropathy &gt; grade 1 Serious nonhealing wound ulcer Patients ( M/F ) reproductive potential implementing adequate contraceptive measure Major surgical procedure , open biopsy significant traumatic injury within 28 day prior start bevacizumab Bleeding disorder coagulopathy need fulldose anticoagulation Signs symptom brain metastasis Cerebrovascular accident transient ischemic attack within past 12 month Impairment gastrointestinal function disease may significantly impair absorption oral drug ( i.e . uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow tablet ) Presence proteinuria baseline define : patient &gt; 1 g protein/24 hr 24hour urine collection . Any concomitant disorder prevent safe administration study drug surgical procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>angiogenesis</keyword>
	<keyword>metabolism</keyword>
</DOC>